Deferred Tax Assets, Operating Loss Carryforwards of NRX Pharmaceuticals, Inc. from 31 Dec 2017 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary
NRX Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD history and change rate from 31 Dec 2017 to 31 Dec 2024.
  • NRX Pharmaceuticals, Inc. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending 31 Dec 2024 was $39,753,000, a 11% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Change (%)

NRX Pharmaceuticals, Inc. Quarterly Deferred Tax Assets, Operating Loss Carryforwards (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $39,753,000 +$3,893,000 +11% 31 Dec 2024 10-K 14 Mar 2025 2024 FY
Q4 2023 $35,860,000 +$2,220,000 +6.6% 31 Dec 2023 10-K 14 Mar 2025 2024 FY
Q4 2022 $33,640,000 +$5,587,000 +20% 31 Dec 2022 10-K 29 Mar 2024 2023 FY
Q4 2021 $28,053,000 +$19,809,000 +240% 31 Dec 2021 10-K 31 Mar 2023 2022 FY
Q4 2020 $8,244,000 +$8,244,000 31 Dec 2020 10-K 31 Mar 2022 2021 FY
Q4 2019 $0 -$21,062,000 -100% 31 Dec 2019 10-K/A 14 May 2021 2020 FY
Q4 2018 $21,062,000 $0 0% 31 Dec 2018 10-K 30 Mar 2020 2019 FY
Q4 2017 $21,062,000 31 Dec 2017 10-K 15 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.